Four transmembrane tyrosine kinase receptors from the EGF receptor (EGFR) or HER proto-oncogene family, which are involved in the etiology of many malignancies, such as ovarian cancer, are known to be significant therapeutic targets. This evidence concerns the gene EGFR and ovarian cancer.